Sirtex in rude health

You wouldn’t know it from the share price, but Sirtex is building a great little business. James Greenhalgh ticks off the milestones.

It’s easy to fall into the trap of judging a company by the performance of its share price. For liver cancer treatment company Sirtex Medical, the stock hasn’t advanced since we commenced coverage in Sirtex enters remission on 8 Nov 10 (Speculative Buy – $5.90). Indeed, the decline from around $6.00 to less than $4.50 over the course of calendar 2011 was probably disheartening.

In an industry like this, progress takes time. But the undeniable fact is that Sirtex’s story has improved significantly over the past 18 months.



{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to proceed...

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access


Updating information

Please wait ...


{{ productPrice }} / day
( GST included )
Price $0
GST $0
Discount -{{productDiscount}}
TOTAL {{productPrice}}
  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership


The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles